ArticleJournal of medicinal chemistry2020
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Efficacy, Structure-Activity Relationship, and Mode of Action Studies of a New Generation of Acridine/Acridone-Based Antimalarials.ACS infectious diseases · 2026Article
- Evaluating acridones as novel therapeutics for human babesiosis.Antimicrobial agents and chemotherapy · 2026Article
- Identification of an Orally Efficacious Imidazo[4,5-Journal of medicinal chemistry · 2026Article
- Potent acridone antimalarial against all three life stages of Plasmodium.Nature communications · 2026Article
- Targeting Mitochondrial Function inInternational journal of molecular sciences · 2025Review
- Identifying antimalarials that disrupt malaria parasite transmission when fed to the mosquito.International journal for parasitology · 2025Article
- Acridone Prodrugs with Enhanced Dual-Stage Antimalarial Efficacy.ACS medicinal chemistry letters · 2025Article
- Development of Next-Generation Antimalarial Acridones with Radical Cure Potential.Journal of medicinal chemistry · 2025Article
- Structure-activity relationships ofExpert opinion on drug discovery · 2022Article
- Antimalarial Natural Products.Progress in the chemistry of organic natural products · 2022Article
- A New Scalable Synthesis of ELQ-300, ELQ-316, and other Antiparasitic Quinolones.Organic process research & development · 2021Article
- Acridones Are Highly Potent Inhibitors ofACS infectious diseases · 2021Article
- Total Synthesis and Antimalarial Activity of 2-(Journal of medicinal chemistry · 2021Article
- (Trifluoromethoxy)Phenylboronic Acids: Structures, Properties, and Antibacterial Activity.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 7 institutions in 2 countries.
Funding
Abstract
The global impact of malaria remains staggering despite extensive efforts to eradicate the disease. With increasing drug resistance and the absence of a clinically available vaccine, there is an urgent need for novel, affordable, and safe drugs for prevention and treatment of malaria. Previously, we described a novel antimalarial acridone chemotype that is potent against both blood-stage and liver-stage malaria parasites. Here, we describe an optimization process that has produced a second-generation acridone series with significant improvements in efficacy, metabolic stability, pharmacokinetics, and safety profiles. These findings highlight the therapeutic potential of dual-stage targeting acridones as novel drug candidates for further preclinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.